Zohydro ER (extended release) is a new opioid-based pain medication just recently approved by the FDA and scheduled to be released for use in March of 2014. More than 40 healthcare organizations, advocacy groups, and physicians have come forward in a desperate appeal to the FDA to revoke the approval of Zohydro ER.
The medication is touted to be many times more potent than standard dosage hydrocodone, and the mounting fear is that Zohydro could lead to immediate abuse and overdose deaths across the country. This concern is in part stemming from the recent explosion in heroin use in the United States and the steady increase in opioid overdose fatalities that has emerged in the last five years.
One characteristic of Zohydro that presents increased risk is that it can be easily crushed and then snorted or injected. The medication was designed specifically for special pain management scenarios in which standard pain management interventions are not effective.
The manufacturers of Oxycontin brought a reformulated version to market some years ago that made if difficult for individuals to crush Oxycontin and misuse it. However, Zohydro was not designed with this tamper-resistant technology included.
Among the professional groups expressing grave concern over Zohydro is ASAM (the American Society of Addiction Medicine). Of particular note too is the fact that 28 State Attorney Generals have urged the Food and Drug Administration to re-examine their decision to approve the drug.
In lieu of the present opioid addiction epidemic that is sweeping the nation, it would seem that Zohydro will likely undergo some modification to insure less abuse potential. To see the drug removed from the market, before it has an irreversible harmful impact, is a goal around which most reasonable people can agree.
For additional reading on the escalation in prescription opioid addiction, review Black Market For Painkillers.
